-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $35

Benzinga·01/21/2026 12:42:05
Listen to the news
Guggenheim analyst Brad Canino initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $35.